Postgraduate Vet Residency and Masters Programmes
Combined 4-year Residency and Masters Programme in Veterinary Clinical Pathology
Graduates with at least one year’s clinical experience are invited to apply for this combined Scholarship and Master`s degree by research. Applicants must be a Member of the Royal College of Veterinary Surgeons or hold a veterinary degree qualifying them for membership. Candidates will be expected to sit examinations of the Royal College of Pathology (Veterinary Clinical Pathology) and to undertake a Master`s degree by research (MVM) in the field of veterinary clinical pathology. The training programme requires participation in the Division’s clinical services, including occasional contribution to the clinical pathology out-of-hours rota, in addition to small-group teaching of veterinary students. Scholarships are renewed annually, subject to satisfactory progress. Initial stipend is £26,875 (PAYE exempt) and rises to £28,217 by the fourth year. £1,500 per annum is available for attendance at conference(s), examination fees and externship costs.
PLEASE ENSURE YOU UPLOAD YOUR CV AS PART OF THE APPLICATION PROCESS.
Closing date for applications: 23 April 2025
The University is committed to equality of opportunity in employment.
University of Glasgow, charity number SC004401
Research Project
The proposed research project is entitled ‘Molecular phenotyping of canine T cell lymphoma’ and aims to investigate gene expression profiles in canine T cell lymphoma. As part of prior work at Glasgow, next generation sequencing (NGS) of canine B and T cell lymphoma samples has identified pathways which predominate in T cell lymphomas, with several genes significantly overexpressed. We plan to use immunohistochemistry to confirm protein expression of some of these genes, using archival FFPE samples. In addition, we will perform mutation analysis on selected genes using our NGS data and follow-up PCR, to identify genes which may play a role in T cell lymphoma. Canine lymphoma is a common disease which is treatable with chemotherapy, however the survival times of individual patients vary considerably. Molecular subtyping in human NHL is helpful for prognostication and is likely to be similar in dogs. Identification of altered gene pathways will help develop the use of novel targeted therapies which may benefit dogs and humans